Exemestane tablets
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Tolmar Inc., Jiangsu Simcere Pharmaceutical Co., Ltd., Shandong Suncadia Medicine Co., Ltd.
Conditions
Breast CancerCYP2D6 PolymorphismLocally Advanced Breast CancerLocally Advanced or Metastatic Breast CancerMetastatic Breast Cancer
Phase 3
A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）
NCT03137368
Start: 2018-08-09End: 2023-10-30Target: 300Updated: 2018-10-31
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
Active, not recruitingNCT04906395
Start: 2021-07-01End: 2026-04-30Target: 250Updated: 2026-01-13
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Enrolling by invitationNCT05645536
Start: 2022-12-28End: 2028-06-30Target: 250Updated: 2026-01-12
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
RecruitingNCT06680921
Start: 2024-11-14End: 2028-08-31Target: 460Updated: 2025-09-22
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
RecruitingNCT07024173
Start: 2025-07-23End: 2027-12-01Target: 240Updated: 2026-01-26
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
RecruitingNCT07349069
Start: 2026-03-04End: 2034-01-01Target: 5500Updated: 2026-05-22